help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-0451
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/11/6296    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Appelhof, B. C.
Right arrow Articles by Fliers, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Appelhof, B. C.
Right arrow Articles by Fliers, E.
Related Collections
Right arrow Thyroid
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 11 6296-6299
Copyright © 2005 by The Endocrine Society


BRIEF REPORT

Polymorphisms in Type 2 Deiodinase Are Not Associated with Well-Being, Neurocognitive Functioning, and Preference for Combined Thyroxine/3,5,3'-Triiodothyronine Therapy

Bente C. Appelhof, Robin P. Peeters, Wilmar M. Wiersinga, Theo J. Visser, Ellie M. Wekking, Jochanan Huyser, Aart H. Schene, Jan G. P. Tijssen, Witte J. G. Hoogendijk and Eric Fliers

Departments of Endocrinology and Metabolism (B.C.A., W.M.W., E.F.), Psychiatry (E.M.W., J.H., A.H.S.), and Cardiology (J.G.P.T.), Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands; Department of Internal Medicine (R.P.P., T.J.V.), Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands; and Department of Psychiatry (W.J.G.H.), VU University Medical Center, 1007 MB Amsterdam, The Netherlands

Address all correspondence and requests for reprints to: Wilmar M. Wiersinga, M.D., Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, F5-171, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands. E-mail: w.m.wiersinga{at}amc.uva.nl.

Introduction: Some patients on levothyroxine replacement display significant impairment in psychological well-being, compared with sex- and age-matched controls. Levothyroxine-treated patients can be assumed to derive T3 exclusively from deiodination of T4, which, in the central nervous system, is regulated by type II deiodinase (DII).

Objective: We investigated whether two recently identified polymorphisms in the DII gene (DII-ORFa-Gly3Asp and DII-Thr92Ala) are determinants of well-being and neurocognitive functioning and associated with a preference for replacement with a combination of T3 and T4.

Methods: Genotypes for both polymorphisms were determined in 141 patients with primary autoimmune hypothyroidism, adequately treated with levothyroxine monotherapy and participating in a randomized clinical trial comparing T4 therapy with T4/T3 combination therapy. Questionnaires on well-being and neurocognitive tests were performed at baseline.

Results: Allele frequencies in patients with primary hypothyroidism were similar to those of healthy blood bank donors (32.0 vs. 33.9% for DII-ORFa-Gly3Asp and 40.4 vs. 38.8% for DII-Thr92Ala). DII polymorphisms were not associated with measures of well-being, neurocognitive functioning, or preference for combined T4/T3 therapy.

Conclusion: The DII-ORFa-Gly3Asp and DII-Thr92Ala polymorphisms do not explain differences in well-being, neurocognitive functioning, or appreciation of T4/T3 combination therapy in patients treated for hypothyroidism.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. Torlontano, C. Durante, I. Torrente, U. Crocetti, G. Augello, G. Ronga, T. Montesano, L. Travascio, A. Verrienti, R. Bruno, et al.
Type 2 Deiodinase Polymorphism (Threonine 92 Alanine) Predicts L-Thyroxine Dose to Achieve Target Thyrotropin Levels in Thyroidectomized Patients
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 910 - 913.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
R. T. Joffe, M. Brimacombe, A. J. Levitt, and A. Stagnaro-Green
Treatment of Clinical Hypothyroidism With Thyroxine and Triiodothyronine: A Literature Review and Metaanalysis
Psychosomatics, October 1, 2007; 48(5): 379 - 384.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. P Peeters, W. M van der Deure, and T. J Visser
Genetic variation in thyroid hormone pathway genes; polymorphisms in the TSH receptor and the iodothyronine deiodinases.
Eur. J. Endocrinol., November 1, 2006; 155(5): 655 - 662.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society